Formulation Development
Cellares Selects Five Best-in-Class Technology Providers to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), recently announced multiple strategic technology partnerships to advance the Cell Q, the first fully automated quality…
Amphista Therapeutics Discloses First Details of SMARCA2 Degrader Program
Amphista Therapeutics recently disclosed first data on its SMARCA2 program including demonstrating exquisite selectivity of its sequentially bifunctional Targeted Glues for SMARCA2 over the closely…
Roivant & Priovant Announce Positive Phase 3 Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis
Roivant and Priovant Therapeutics recently announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM). On the primary endpoint, brepocitinib 30…
Pneumagen Launches NeumoBind Technology Platform to Unlock New Opportunities in Intranasal Therapeutics
Pneumagen, a clinical-stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections, announces a…
Rein Therapeutics Announces New Translational Data on its Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics recently announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press.…
Arch Strengthens its Position as a Leading Kidney Therapeutics Company With Acquisition of Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease
Arch Biopartners Inc. recently announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). The platform includes recently filed…
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate
Osivax recently announced the first participant has been vaccinated in its Phase 2b clinical trial (NCT05569239) evaluating OVX836, the company’s broad-spectrum influenza A vaccine candidate.…
Terumo Blood & Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America
In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo…
Areteia Therapeutics Announces Positive Topline Results From First Phase 3 Study of Oral Dexpramipexole in Eosinophilic Asthma
Areteia Therapeutics, Inc. recently announced positive results from the Phase 3 EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants…
FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers
FORE Biotherapeutics recently presented new plixorafenib results from the previously completed Phase 1/2a clinical trial that demonstrate treatment with plixorafenib in patients with BRAF-altered papillary…
Upperton Wins Pharma Contract Services Company of the Year at the Pharma Industry Awards UK 2025
Upperton Pharma Solutions has added another impressive award to a growing list of achievements, winning the award for Pharma Contract Services Company of the Year…
Monte Rosa Therapeutics Announces Collaboration With Novartis for Degraders to Treat Immune-Mediated Diseases
Monte Rosa Therapeutics, Inc. recently announced an agreement to collaborate with Novartis to develop novel degraders for immune-mediated diseases. The agreement is the company’s second…
Abzena Enhances AbZelectPRO Cell Line Offering With New GS Knockout Platforms
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch…
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio
Cadrenal Therapeutics, Inc. recently announced the acquisition of the assets of eXIthera Pharmaceuticals, including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa…
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 Trial of the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Spyre Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 2 SKYWAY basket trial evaluating SPY072 in RA, PsA, and axSpA.…
Department of Defense Awards Grant to Advance Tiziana Life Sciences' Intranasal Anti-CD3 Therapy for Spinal Cord Injury
Tiziana Life Sciences, Ltd. recently announced that the US Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3…
Belite Bio Announces Completion a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Belite Bio Inc. recently announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt…
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach & Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics Corp. recently announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor…
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients With Solid Tumors
Trethera Corporation recently announced the final patient has enrolled in its Phase 1 dose escalation trial for the treatment of advanced solid tumors. Patients have…
Symeres Acquires DGr Pharma to Enhance Regulatory Expertise & Broaden Biopharma Capabilities
Symeres recently announced the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for…
